P&T Perspectives

Real P&T Professionals. Real Market Research.

Exposing potential obstacles through market research with unbiased and objective insights from P&T decision-makers is critical.

MMIT P&T Perspectives provides qualitative and tangible feedback through a realistic simulated P&T session that informs your individual brand strategy and enables you to understand how your product and/or competitor’s product will fare in an actual P&T Committee review.

Learn More


icon-website

Predict

Predict how a P&T Committee might evaluate your drug against competitors.

icon-website

Understand

Understand how pricing could impact your drug’s placement on formulary.

icon-website

Identify

Identify the types of coverage restrictions that could be placed on your therapy and competitors.

icon-website

Improve

Improve your drug’s launch trajectory by identifying the most competitive contracting scenarios.

Features

How We Help

MMIT's industry-leading P&T panel consists of pharmacy decision-makers at health plans, PBMs, providers and integrated delivery systems. 100% of panelists are either active P&T participants or control access for pharmaceuticals for their organizations, giving you unparalleled visibility into these entities.

Simulate

Simulate a typical payer or IDN P&T committee, including a pharmacy director, medical director, contracting executives, and physicians and disease state specialists.

Analyze

Analyze a clinical dossier developed autonomously by a clinical pharmacist, with the opportunity to provide additional clinical data and/or target product profile.

Observe

Observe a 90 minute live-streamed session, including a 45 minute clinical overview and discussion based on the clinical dossier and a 45 minute financial overview and discussion led by the contracting pharmacist.

Question

Ask specific questions of the double-blinded participants during a 15-minute Q&A session after the P&T meeting concludes.

View Samples of Recent P&T Sessions
Showcase 1
PlayPlay
Showcase 1
PlayPlay
Showcase 1
PlayPlay
Showcase 1
PlayPlay
previous arrowprevious arrow
previous arrowprevious arrow
next arrownext arrow
next arrownext arrow
Slide 3
Additional Resources
Use Case
Syndicated P&T Session
A pharma company with several approved brands with large market share was developing a new Crohn’s disease drug. The company partnered with MMIT to determine whether the new drug would be approved in the marketplace.
Case Study
Preparing for Launch with P&T Perspectives
Learn how a P&T review helped one pharma company understand how its product would be assessed, leading to a new focus on gathering real-world evidence.
Webinar Recording
Understanding the Impact of Humira Biosimilars on Market Access
Explore how we can expect the market to react and how factors such as launch timing, interchangeability, and contracting will shape the immunology landscape.